Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC

BACKGROUND: Anaplastic lymphoma kinase (ALK)–tyrosine kinase inhibitors (TKIs) have been approved for the therapy of locally advanced non-small cell lung cancer (NSCLC) caused by ALK rearrangement. However, its treatment after failure of initial ALK–TKI therapy remains controversial. CASE PRESENTATI...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Hiroshi, Komori, Kazuyuki, Kameda, Koji, Taguchi, Shinichi, Ozeki, Yuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976869/
https://www.ncbi.nlm.nih.gov/pubmed/35366157
http://dx.doi.org/10.1186/s40792-022-01408-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976869/
https://www.ncbi.nlm.nih.gov/pubmed/35366157
http://dx.doi.org/10.1186/s40792-022-01408-7

Ejemplares similares